Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells
Authors:
Open Access
- 16 June 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (32) , 51747-51762
Abstract
Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cellsKeywords
This publication has 60 references indexed in Scilit:
- 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, 1 a novel resveratrol analog, differentially regulates estrogen receptors α and β in breast cancer cellsToxicology and Applied Pharmacology, 2016
- Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugsPharmacology & Therapeutics, 2013
- Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancerBMC Cancer, 2013
- Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancerCarcinogenesis, 2012
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2011
- A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallateBritish Journal of Cancer, 2008
- Estrogen-induced breast cancer: Alterations in breast morphology and oxidative stress as a function of estrogen exposureToxicology and Applied Pharmacology, 2008
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTJournal of Clinical Oncology, 2008
- Mechanisms of tamoxifen resistanceEndocrine-Related Cancer, 2004
- A Unifying Mechanism in the Initiation of Cancer and Other Diseases by Catechol QuinonesAnnals of the New York Academy of Sciences, 2004